LOS ANGELES, Nov. 29, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...

Humacyte has a 52 week low of $2.45 and a 52 week high of $9.97. The stock has a 50-day moving average price of $5.24 and a 200 day moving average price of $6.17.

SAN FRANCISCO, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...

Humacyte, Inc. (HUMA) Securities Class Action: The complaint, filed on behalf of investors who purchased Humacyte securities between May 10, 2024, and October 17, 2024, claims that the company and its ...

NEW YORK, Nov. 25, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte ...

Humacyte, Inc. (HUMA) Securities Class Action: The complaint, filed on behalf of investors who purchased Humacyte securities between May 10, 2024, and October 17, 2024, claims that the company and ...

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10 ...

If you suffered a loss in Humacyte you have until January 04, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as ...

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s (NASDAQ:HUMA) stock at an average price of US$6.64 in the past 12 months may be dismayed by the recent 17% price decline. Insiders ...